We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Chromogenex | LSE:CGX | London | Ordinary Share | GB00B0B7XX32 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.325 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number : 0097A Chromogenex PLC 28 July 2008 Chromogenex plc ("Chromogenex" or "the Company") Preliminary Results Chromogenex the developer and manufacturer of cosmetic and medical laser systems today announces its preliminary results for the year ended 31 December 2007. Highlights: * Revenues of £4.12m (2006: £4.46m) * Loss before tax £697k (2006: profit £335k) * Launch of Nicolite laser for the cessation of smoking * Cellulite reducing laser due for launch in 2008 * Anticipated return of Canadian sales in Q2 2008 following initial licence validation setback * Launch of Chromolite EP with FDA approval granted in July 2008 Peter McGuinness, Chairman, commented: "2007 was a year of change for the company. Following a slow start to the year and a change of management the business achieved consistent growth in sales particularly in the final quarter. "Whilst the first half and in particular the first quarter of 2008 has been impacted by no sales to Canada and a general industry slowdown, the Board expects an improvement in performance in the second half as a result of a cost reduction plan implemented recently and the launch of three new products in the third quarter in the area of laser assisted liposuction, body shaping and cellulite treatment, the main growth sector of the industry. "We have recently launched our Enhanced Pulse model (EP) of the Chromolite and see significant opportunities to upgrade over 1,700 existing systems worldwide. We expect to see increased sales of our higher margin products in 2008 thereby improving our gross margin and overall profitability. We have a number of new products in the pipeline which will contribute to sales in the second half of 2008 and beyond." For further information: Chromogenex plc 020 8434 0540 Peter McGuinness, Chairman 07775 834 777 HB Corporate 020 7510 8600 Luke Cairns Threadneedle Communications 020 7936 9605 Graham Herring/Josh Royston We are pleased to present the consolidated accounts of Chromogenex plc and its subsidiaries for the year ended 31 December 2007. Introduction and overview 2007 was a year of change for the company. Following a slow start to the year and a change of management the business achieved consistent growth in sales particularly in the final quarter. At year end, the company was on track for achieving strong sales growth, however, following notification from the Canadian Health Authority regarding validity of licences for two key products, the company reversed sales in this territory resulting in a loss for the year and sales lower than budget. The company invested significantly in R&D throughout the year to upgrade our existing Chromolite product and develop new products to treat cellulite and fat reduction as well as the Nicolite laser which is clinically proven to help people stop smoking. The Nicolite was launched during the year and the cellulite system is due for launch in 2008. Sales of our Nlite laser for treating acne, skin rejuvenation and vascular lesions have improved by 46% whilst sales of Chromolite were down 26% in part due to the expected release of the new Enhanced Pulse model in 2008. Sales of service and consumables increased by 19%. Results Revenue for the year was down 8% to £4,122,000 (2006: £4,462,000) which was lower than expected as a result of reversal of sales to Canada at year end. Gross margin has reduced to 30% (2006: 46.8%) as a result of increased sales of our Nlite laser, which carry lower gross margins as a percentage of overall sales and lower sales of Chromolite which contributed higher margins. A significant portion of R&D costs were expensed in the year. This, along with other factors, has resulted in a net loss of £697,000. Excluding R&D expenditure the Earnings before Interest Tax Depreciation and amortisation (EBITDA) amounted to a loss of £312,000 (2006: profit of £413,000). The (loss)/earnings per share is (1.15)p (2006: 0.51p). At the year-end, the Group had net assets of £1,688,000 (2006: £2,347,000) with cash at bank of £130,000 (2006: £362,000). Overview and Future Outlook The lack of sales to Canada and the current tough prevailing market conditions has led to a challenging first half of 2008. Regulatory Approval for our Chromolite S and Regenlite (formerly NLite) products for sale in the Canadian market has now been received. The Board has acted to reduce the group's cost base by improvements in cross-skilling and further simplification of business processes. Increased emphasis has been placed on the higher margin direct sales in the UK market which are backed by finance leases, thereby improving cashflow We have recently launched our Enhanced Pulse model (EP) of the Chromolite and see significant opportunities to upgrade over 1,700 existing systems worldwide. We expect to see increased sales of our higher margin products in 2008 thereby improving our gross margin and overall profitability. We have a number of new products in the pipeline which will contribute to sales in the second half of 2008 and beyond. Long term strategy and business objectives Chromogenex plc (*CGX*) designs, manufactures and distributes aesthetic and therapeutic laser and aesthetic light based technology devices. The Group has developed this light based technology and holds a number of patents in respect of it. It has two main multifunctional products: · The Chromolite* - an intense Xenon pulse light system for permanent hair reduction, skin rejuvenation, treatment of pigmented lesions and other applications ; and · RegenLite*, a 585mm pulse dye laser used for the treatment of Acne Vulgaris and other clinical skin lesions, as well as for aesthetic skin rejuvenation. The Group has already established a market presence in the UK, USA and Europe by manufacturing and distributing in excess of 500 Nlite*-V laser systems to over 40 countries. During 2007 CGX released Nicolite, a low level laser for treatment of nicotine addiction. Backed by double blind studies Nicolite is proven to be six times more effective than nicotine patches. It is the directors* intention to continue to expand the Group*s business worldwide and accordingly, the directors have developed a strategy for the Group as follows: · Geographic expansion. The Group has been under-represented in the US and developing this market more fully is a major opportunity; · Continued development of existing products and development of future products. The Group is aware of the problem with obesity and fat related conditions which are quickly getting more media coverage and the Directors see this as a potentially large market place in which to exploit; and · Acquisition of businesses with complementary skills, technologies and products. Results for 2007 financial year Revenue There has been a fall in revenue during the year of 8%. This is in spite of healthy increases in revenue from N-lite which is up 46% and revenue from sales and spares has increased by 47%. Although the new Chromolite S was launched during the year the overall revenues from the Chromolite product range have fallen by 26% during the year. The international sales as a percentage of total sales, has increased to 78% from 74% over the past year. Operations Over the past year, the Group has further increased manufacturing capacity through the introduction of more efficient processes. The Group has upgraded its quality systems during the year to ISO 13485/2003 and was further awarded ISO 9000/2000 Certification. The US Food and Drugs Administration has given clearance for Chromolite*; and also certification to the Canadian CMDCAS quality requirement has been granted for both Chromolite* and N-Lite*. Chromolite* has been manufactured since 2004 and at the beginning of 2007 the 1,000th Chromolite* was shipped to a customer in France. Financial Review Revenue Revenue has fallen by 8% to £4,122,000 (2006: £4,462,000) generating an operating loss of £695,000 (2006: operating profit restated: £339,000). The fall in revenue and operating loss has arisen primarily as a result of problems encountered with the sale of Chromolite products, particularly in Canada, where regulatory approval has now been obtained on the part of the Company and its distributor to satisfy the registration requirements for the products being sold in this market. Gross Margin and underlying Operating Profit The Gross profit percentage has fallen to 30%. (2006: 47%). These are lower than the previous year due to reduced Chromolite sales and increased sales of Nlite, which has lower gross margins. Administrative expenses have increased by 11% to £1,938,000 (2006: £1,748,000). Research and development expenditure has increased to £283,000 (2006: £58,000). Staff costs have fallen in the year to £1,126,000 (2006: £1,217,000) whilst staff numbers have risen to 42 (2006: 37). Operating profit is the net profit of the business before taxation and financing costs. The 2006 Operating Profit has been restated to reflect the change from UK Generally Accepted Accounting Principles to International Financial Reporting Standards. As a result of this restatement (see note 19) operating profit is £158,000 lower at £339,000. In 2007 there is an operating loss of £695,000. Taxation The availability of tax losses brought forward amounting to £8,500,000 will reduce taxable profits to £nil in the current year; and consequently there is no tax charge. Earning per share Basic earnings per share has fallen to a loss of 1.15p (2006: restated earnings per share of 0.56p). The diluted earnings per share has fallen to a loss of 1.15p (2006: restated earnings per share of 0.51p). Development Expenditure During the year the costs of developing Chromolite EP amounting to £81,000 have been capitalised. Costs relating to other products were fully expensed in the year. Capital Structure Under the terms of an Instrument dated 14 December 2004 the company issued 2,500,000 warrants to subscribe for ordinary shares of 1p each, at a price of 4p per share. These warrants are exercisable between 20 June 2005 and 19 June 2008. During the 2007 year 437,500 warrants have been exercised (2006: 1,312,500 warrants were exercised at 4p per share). At the end of the year 750,000 warrants remained outstanding (2006: 1,187,500 options outstanding). In June 2007 the Company granted options over 2,000,000 ordinary shares at 6.5p per share. At 31 December 2007, options over 5,200,000 ordinary shares were outstanding (2006: 6,000,000 options outstanding). Cash Flow There was a net cash outflow from operating activities of £133,000 (2006: £288,000 inflow). This was attributable to the operating loss for the year compared with the operating profit in the previous year. There was a fall in cash balances in the year to £130,000 (2006: £362,000). Future Outlook Whilst the first half and in particular the first quarter of 2008 has been impacted by no sales to Canada and a general industry slowdown, the Board expects an improvement in performance in the second half as a result of a cost reduction plan implemented recently and the launch of three new products in the third quarter in the area of laser assisted liposuction, body shaping and cellulite treatment, the main growth sector of the industry.. We have taken action to reduce our cost base and staffing levels to reflect a more challenging market. We are focused on continuing to improve direct high margin sales in the UK and this will improve cashflow going forward. After an extended beta test phase our Enhanced Pulse model (EP) of the Chromolite has seen a successful launch and we see significant opportunities to upgrade over 1,700 existing systems worldwide. We expect to see increased sales of our higher margin products in 2008 thereby improving our gross margins. We are cautiously confident that new products for fat reduction and body shaping, an area of growing demand in the market, will contribute to sales in the second half of 2008 and beyond. Peter McGuinness Chairman Consolidated Income Statement For the year ended 31 December 2007 2007£*000 2006£*000 REVENUE 4,122 4,462 Cost of sales (2,879) (2,375) -------------------- -------------------- -------------------- -------------------- -- -- Gross profit 1,243 2,087 Administrative expenses (1,938) (1,748) -------------------- -------------------- -------------------- -------------------- -- -- OPERATING (LOSS)/PROFIT (695) 339 Interest payable and similar (2) (4) charges -------------------- -------------------- -------------------- -------------------- -- -- (LOSS)/PROFIT BEFORE TAXATION (697) 335 Taxation - - -------------------- -------------------- -------------------- -------------------- --- --- (LOSS)/PROFIT FOR FINANCIAL YEAR (697) 335 ==================== ==================== ==================== ==================== == == (LOSS)/EARNINGS PER ORDINARY SHARE (PENCE) Basic (1.15)p 0.56p Diluted (1.15)p 0.51p ==================== ==================== ==================== ==================== == == All results relate to continuing activities. The loss for the year (2006: profit) is wholly attributable to the equity shareholders of the company. Consolidated Statement of Changes in Equity For the year ended 31st December 2007 Attributable to equity holders of the parent company Share Share premium Merger Retained Total capital account reserve Earnings Equity £'000 £'000 £'000 £'000 £'000 At 1 January 2006 592 1,500 (302) 75 1,865 Profit for the year - - - 335 335 Share option costs - - - 95 95 Exercise of warrants 13 39 - - 52 _______ _______ _______ _______ _______ At 1 January 2007 605 1,539 (302) 505 2,347 Loss for the year - - - (697) (697) Exercise of warrants 4 14 - - 18 Share option costs - - - 20 20 _______ _______ _______ _______ _______ At 31 December 2007 609 1,553 (302) (172) 1,688 _______ _______ _______ _______ _______ Consolidated Balance Sheet As at 31 December 2007 2007 2006 Notes £'000 £'000 ASSETS Non-Current Assets Intangible assets 79 343 Property, plant and equipment 60 64 -------------------- ---------------------- -------------------- -------------------- -- 139 407 -------------------- ---------------------- -------------------- -------------------- -- Current Assets Inventory 1,777 1,245 Trade and other receivables 866 1,226 Cash and cash equivalents 130 362 -------------------------- ------------------------------------------ ---------------- 2,773 2,833 LIABILITIES Current Liabilities Trade and other payables (1,126) (843) Provisions (98) (50) -------------------------- ------------------------------------------ ---------------- (1,224) (893) -------------------------- ------------------------------------------ ---------------- NET CURRENT ASSETS 1,549 1,940 -------------------------- ------------------------------------------ ---------------- TOTAL ASSETS LESS CURRENT 1,688 2,347 LIABILITIES -------------------------- ------------------------------------------ ---------------- NET ASSETS 1,688 2,347 ========================== ========================================== ================ SHAREHOLDERS' EQUITY Called up share capital 609 605 Share premium 1,553 1,539 Merger reserve (302) (302) Retained Earnings (172) 505 -------------------- -------------------- -------------------- -------------------- -- -- TOTAL EQUITY (attributable to 1,688 2,347 equity holders of the parent) ==================== ==================== ==================== ==================== == == Consolidated Cash Flow Statement For the year ended 31st December 2007 2007 2006 Notes £'000 £'000 NET CASH FLOW FROM OPERATING ACTIVITIES (133) 288 INVESTING ACTIVITIES Purchase of intangible assets (81) (190) Property, plant and equipment (34) (61) -------------------- -------------------- -------------------- -------------------- -- -- NET CASH OUTFLOW FROM INVESTING ACTIVITIES (115) (251) FINANCING ACTIVITIES Proceeds from the issue of shares 18 52 Bank and other interest paid (2) (4) -------------------- -------------------- -------------------- -------------------- -- -- NET CASH INFLOW FROM FINANCING ACTIVITIES 16 48 -------------------- -------------------- -------------------- -------------------- -- -- (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS IN (232) 85 YEAR ==================== ==================== ==================== ==================== == == 2007 2006 £'000 £'000 Movement in cash and cash (232) 85 equivalents Opening cash and cash 362 277 equivalents --------------------- ------------------------------------------ --------------------- CLOSING CASH AND CASH 130 362 EQUIVALENTS ===================== ========================================== ===================== NOTES TO THE FINANCIAL STATEMENTS for the year ended 31 December 2007 1 ACCOUNTING POLICIES BASIS OF PREPARATION Going concern During the year, the Group incurred a loss of £697,000, compared to a profit in the previous year, and expects to report further losses for the six months to 30 June 2008. As a result of the Group's financial position, the directors have considered the basis of preparation of the financial statements on the going concern basis. In the light of the current market downturn the Board has been reconsidering its strategy and has made a number of decisions to re-focus the activities of the Group. The Board has streamlined the underlying cost base of the business, started to distribute two new complementary products into the UK market and has now obtained all regulatory approvals required in order to sell into the Canadian market. Payment plans are in place with most of the overdue debtors as at the year end. The directors have prepared detailed forecasts which set out the ongoing cash requirements of the business going forward. The directors maintain regular communication with the bank and these forecasts incorporate the directors' belief that the Group's bankers will continue to make available, after the formal review in September 2008, the level of facility that is currently available. There are inherent uncertainties in the preparation of such forecasts which are not fully under the Group's control. Historically the Group has delivered greater sales in the second half of the year and the directors expect this trend to continue with the planned introduction of further new products in the autumn. The directors therefore believe the assumptions used in those forecasts are reasonable and that they have taken into account all factors that may reasonably be expected to be identified in relation to such forecasts. On the basis of these forecasts the directors conclude that it is appropriate to prepare the financial statements on the going concern basis and the financial statements do not include any adjustments that would result from the Group not being able to meet its liabilities as they fall due. International Financial Reporting Standards These financial statements have been prepared in accordance with International Financial Reporting Standards ('IFRS'), as adopted by the European Union, and with those parts of the Companies Act 1985 applicable to companies reporting under IFRS. In preparing the underlying financial information the Directors have applied certain first time adoption provisions allowed by IFRS 1. These standards remain subject to ongoing amendment and / or interpretation and are therefore still subject to change. Accordingly, information contained in these financial statements may need updating for subsequent amendments to IFRS required for first time adoption or for new standards issued post balance sheet date. At the date of authorisation of these financial statements, the following Standards and Interpretations which have not been applied in these financial statements were in issue but not yet effective: Amendment to IAS1 - Presentation of financial statements Amendment to IFRS3 - Business combinations Amendment to IAS27 - Consolidated and separate financial statements IAS23 (Amended) - Borrowing costs IFRS 8 - Operating Segments IFRIC 11 - Group and Treasury Share Transactions IFRIC 12 - Service Concession Arrangements IFRIC 13 - Customer loyalty programmes IFRIC 14 - IAS19 - The limit on a defined benefit asset, minimum funding requirements and their interaction. Amendment to IFRS3 - Share based payment - vesting conditions and cancellations Amendment to IAS32 - Financial Statements The directors anticipate that the adoption of these Standards and Interpretations in future periods will have no material impact on the financial statements of the Group when the relevant standards and interpretations come into effect. The Group has established IFRS accounting policies for the year ended 31 December 2007 and applied these policies and the opening balance sheet at its date of transition being 1 January 2006. The impact of transition from UK GAAP to IFRS on Group shareholders' equity as at 31 December 2006 and on the date of transition of 1 January 2006, and on the Group's income statement for the year ended 31 December 2006 is outlined in note 19. The transition to IFRS has not affected the company's cash flows. The preparation of financial statements in accordance with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise judgement in the process of applying the accounting policies. The notes to the financial statements set out areas involving a higher degree of judgement or complexity, or areas where assumptions are significant to the financial statements such as intangible assets. In particular, the directors regularly review the commercial viability of development projects and make estimates on the level of amortisation based upon the quantum and timing of future revenues from those products (see note 9). Although these estimates are based upon management's best knowledge of the amount event or actions, actual results may ultimately differ from those estimates. Transitional arrangements The adoption of the provisions set out in IFRS 1 is set out below. * Business combinations: a first time adopter may elect not to apply IFRS 3 - 'Business combinations' retrospectively to business combinations that occurred before the date of transition to IFRS. The Group elected to take advantage of this exemption, not applying IFRS 3 to the business combinations that occurred before 31 December 2005 the Group's date of transition. * Share-based payments: the Group has applied the requirements of IFRS 2 - 'Share-based payments' in accordance with the transitional provisions. IFRS 2 has been applied to all grants of equity instruments after 1 July 2005 that had not vested at 31 December 2005. The financial statements have been prepared under the historical cost convention and in accordance with applicable accounting standards. BASIS OF CONSOLIDATION The consolidated financial information comprise the financial information of Chromogenex plc and its subsidiary undertakings. All business combinations occurred prior to the date of transition and were accounted for in accordance with the transitional arrangements set out above. 2 TAXATION Current tax: 2007 2006 £'000 £'000 In respect of the current year - - Over provision in prior years - - -------------------- --------------------------- ------- - - ==================== ========================== ====== Factors affecting the tax charge The tax assessed for the years are lower than the applicable rate of corporation tax in the UK. The difference is explained below: 2007 2006 £'000 £'000 (Loss)/profit on ordinary (697) 335 activities before tax ==================== ==================== ============ ============ (132) 64 (Loss)/profit on ordinary activities multiplied by the standard rate of tax in the UK (19%) Effects of: Expenses not deductible/income 16 (3) not taxable Accelerated capital allowances 7 1 Losses utilised/carried 109 (62) forward -------------- -------------- Total current tax - - ============== ============== The group has tax losses of approximately £8.5 million (2006: £8.5 million) available to carry forward to offset against future profits or to be surrendered in respect of Research and Development tax credit claims, subject to agreement by HM Revenue & Customs. 3 EARNINGS PER ORDINARY SHARE The earnings per ordinary share has been calculated using the profit for the year and the weighted average number of ordinary shares in issue during the year as follows: 2007 2006 £'000 £'000 (Loss)/Profit for the year after taxation (697) 335 _______ _______ No. No. Basic weighted average of ordinary shares 60,659,747 59,519,417 of 1p each _____ __ ____ ___ Basic earnings (pence per share) (1.15)p 0.56p _______ _______ Fully diluted earnings (pence per share) (1.15)p 0.51p _______ _______ The weighted average number of shares for the calculation of diluted earnings per share at 31 December 2007 was 63,920,534 (2006: 65,349,352) reflecting the unexercised share options and warrants in place. As the Group is reporting a loss for the period then, in accordance with IAS33, the share options are not considered dilutive because the exercise of the share options would have the effect of reducing the loss per share. 4 SHARE CAPITAL 2007 2006 No. No. Authorised 1p ordinary shares 500,000,000 500,000,000 ========================== ============================================== ==================== Allotted, issued and fully paid 1p ordinary shares 60,931,818 60,494,318 ========================== ============================================== ==================== 2007 2006 £'000 £'000 Authorised 1p ordinary shares 5,000 5,000 ========================== ============================================== ==================== Allotted, issued and fully paid 1p ordinary shares 609 605 ========================== ============================================== ==================== The following share warrants were exercised at 4p per share during the period to 31 December 2007. 5 February 2007 375,000 1 May 2007 62,500 ----------------------------------------- 437,500 ========================================== The Company has one class of ordinary shares which carry no right to fixed income. 6 CASH FLOWS 2007 2006 £'000 £'000 A Reconciliation of operating (loss)/profit to net cash flow from operating activities Operating (695) 339 (loss)/profit Amortisation 345 - Depreciation 38 74 Movement in (532) (26) inventory Movement in trade 360 (348) and other receivables Movement in trade 331 154 and other payables Share option costs 20 95 -------------------- -------------------- ------------ ------------ Net cash flow from (133) 288 operating activities ==================== ==================== ============ ============ 2007 2006 £'000 £'000 B Analysis of change of net funds Opening cash and 362 277 cash equivalents Movement in cash and (232) 85 cash equivalents --------------------- -------------------------------- ----------- Closing cash and 130 362 cash equivalents ===================== ================================ =========== 7 RECONCILIATION OF NET ASSETS AND LOSS UNDER UK GAAP TO IFRS Chromogenex plc reported under UK GAAP in its previously published financial statements for the year ended 31 December 2006. The analysis below shows the reconciliation of profit and net assets as reported under UK GAAP as at 31 December 2006 and the revised net assets and profit under IFRS as reported in these financial statements. In addition there is a reconciliation of equity under UK GAAP to IFRS at the transition date for the Group being 1 January 2006. Group Reconciliation of loss for the year 31 Dec 2006 £'000 Profit for the year reported under UK GAAP 493 Adjustments - Amortisation of negative goodwill (158) _______ Profit for the year reported under IFRS 335 Group Reconciliation of shareholders' equity 31 Dec 2005 31 Dec 2006 £'000 £'000 Shareholders' equity reported under GAAP 1,707 2,347 Adjustments - Amortisation of negative goodwill 158 - _______ _______ Shareholders' equity for the year reported under IFRS 1,865 2,347 _______ _______ In accordance with IFRS 3, negative goodwill as at 1 January 2006 amounting to £158,000 has been written back to Retained Earnings as at that date. The amortised goodwill previously credited to the Profit and Loss account in the periods ending 31 December 2006 has also been written back. The consolidated cash flow statement presents substantially the same information as that required under UK GAAP. This information is provided by RNS The company news service from the London Stock Exchange END FR PUUMUMUPRGGR
1 Year Chromogenex Chart |
1 Month Chromogenex Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions